Eric Daniels was named Chief Operating Officer of Cerenome, Inc. As of November 14, 2026, Cerenome, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 13, 2026 to November 12, 2026, naming 4 appointments and 1 departure (Form 8-K, November 12, 2026).
CERENOME, INC. named a new Director on Nov 12. 29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Cerenome, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Ronald A. Andrews · Role: Director · 8-K, 2026-11-12
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-09
- · In / out: In · Person: Ronald A. Andrews · Role: Director · 8-K, 2026-03-26
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-02-13
Cerenome, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-13 to 2026-11-12. They name 3 people, with 4 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Cerenome, Inc. files it.
Also on the record for Cerenome, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 18, 2026 | Form D, private offering | $3M sold | Form D page | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Highbridge Capital Management, LLC | 7.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 4.9% of the class | 5%+ stakes | Source |
| January 22, 2026 | Stake report, Schedule 13G, by CVI Investments, Inc. | 6.9% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by S.H.N. Financial Investments Ltd. | 1.51% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G/A, by Orin Hirschman | 3.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Cerenome, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Cerenome, Inc. and the records around it.
Cerenome, Inc. elsewhere on the record
- Form D filing Sep 2026
- Who owns it
Companies that share a holder
- S.H.N. Financial Investments Ltd. also filed stake reports on 20 other companies: DarkIris Inc. (Nov 2026), NFT Ltd (Nov 2026), NetClass Technology Inc (Nov 2026)
- Orin Hirschman also filed stake reports on 46 other companies: ASPEN AEROGELS, INC. (Oct 2026), Bionano Genomics, Inc. (Oct 2026), FENNEC PHARMACEUTICALS INC. (Oct 2026)
- CVI Investments, Inc. also filed stake reports on 48 other companies: Pine Tree Acquisition Corp. (Oct 2026), Sunshine Biopharma Inc. (Oct 2026), Outlook Therapeutics, Inc. (Aug 2026)
Watch Cerenome, Inc.
Get an email when Cerenome, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cerenome, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cerenome, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cerenome, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-12 | In | Director | 8-K, 2026-11-12 | ||
| 2026-11-12 | In | Chief Operating Officer | 8-K, 2026-11-12 | ||
| 2026-04-09 | Reported | not named in the filing | 8-K, 2026-04-09 | ||
| 2026-03-26 | In | Director | 8-K, 2026-03-26 | ||
| 2026-03-26 | In | 8-K, 2026-03-26 | |||
| 2026-03-26 | Out | Director | 8-K, 2026-03-26 | ||
| 2026-02-13 | Reported | not named in the filing | 8-K, 2026-02-13 |
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Robert Lenk, Director (filed 2026-03-26):
Dr. Lenk informed the Company that his resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Who leads Cerenome, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Operating Officer: Eric Daniels, appointed (filed 2026-11-12).
- Director: Ronald A. Andrews, appointed (filed 2026-11-12).
New leaders reset buying decisions — get the Full Report on Cerenome, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Cerenome, Inc., with the record behind each one.
Find candidates like Director at Cerenome, Inc.Every change, in the filing's words
Appointed: Ronald A. Andrews, Director
Prior to his appointment as Chief Business Officer, Mr. Andrews was appointed to our board of directors in March 2026.
Appointed: Eric Daniels, Chief Operating Officer
Mr. Andrews has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K. 1 Appointment of Eric Daniels, M.D., as Chief Operating Officer On November 6, 2026, the Company's board of directors promoted Eric Daniels, M.D., as its Chief Operating Officer.
- Appointment of Ronald A. Andrews as Chief Business Officer On November 10, 2026, Cerenome, Inc. (the "Company") announced the appointment of Ronald A. Andrews as Chief Business Officer of the Company ("CBO"), effective November 9, 2026.
- Mr. Andrews, age 67, will be responsible for advancing enterprise growth strategy, strategic partnerships, corporate development, and business opportunities across the Company's diagnostics, therapeutics, and data analytics platforms.
- Mr. Andrews is also currently serving as Founder, Managing Partner of The Bethesda Group, which is a strategic consulting firm focused on helping organizations in the molecular diagnostic/genomic market segments with strategy, commercial execution, C-suite mentorship and fractional C-suite support.
- From April 2023 to July 2024, Mr. Andrews served as President and CEO of Twin Strand Biosciences and from July 2016 to December 2022 as President and CEO of Oncocyte Inc. (NASDAQ: OCX).
- From July 2015 to July 2019 he worked as Founder and Senior Partner of The Bethesda Group and from September 2013 to February 2015 he was President, Genetic Sciences Division, at Thermo Fisher Scientific/ Life Technologies (NASDAQ:TMO).
Reported
Appointment of Eric J. Daniels, M.D. as Chief Development Officer On April 9, 2026, Plus Therapeutics, Inc. (the "Company") announced the appointment of Dr. Eric J. Daniels as Chief Development Officer of the Company, effective April 20, 2026.
- Dr. Daniels, age 53, will be responsible for the development and ultimate approval of the Company's pharmaceutical pipeline effective upon the commencement of his employment with the Company.
- Prior to joining the Company, from October 2021 through April 2026, Dr. Daniels served as the chief development officer of Kiora Pharmaceuticals (NASDAQ:KPRX).
- In addition, from 2018 through 2021, Dr. Daniels served as the executive director and co-founder of Bayon Therapeutics until it was acquired by Kiora Pharmaceuticals in October 2021 and as chief executive officer of OccuRx Pty Ltd., a clinical stage biotechnology company targeting microvascular disease for ocular indications, from July 2020 through October 2021.
- Dr. Daniels is also a co-founder and director of Okogen, Inc., a specialty biotechnology development stage ophthalmic company focused on a novel therapeutic for the treatment of viral infections of the eye, since May 2016.
- Since January 2014, Dr. Daniels has served on the clinical advisory board of Bimini, LLC and was chief medical officer of Bimini from January 2014 to October 2021.
- From April 2012 to November 2016, Dr. Daniels served as vice president - marketing & sales for Tensys Medical, Inc. (an HBM portfolio company).
Appointed: Ronald A. Andrews, Director
Appointment to Board of Directors On March 20, 2026, the Board of Directors (the "Board") of Plus Therapeutics, Inc. (the "Company") unanimously appointed Mr. Ronald A. Andrews to serve as a director of the Board, effective immediately.
Appointed: Ronald A. Andrews
Mr. Andrews was appointed to our Board in March 2026.
Departing: Robert Lenk, Director
Resignation from Board of Directors On March 20, 2026, Robert Lenk resigned as a member of the Board and a member of the Nominating and Corporate Governance Committee.
- Mr. Andrews is being appointed to the Board to fill the vacancy created by the resignation of Dr. Robert Lenk and is expected to stand for reelection at the Company's 2026 annual meeting of stockholders.
- The Board has determined that Mr. Andrews satisfies the definition of an "independent director" under the Nasdaq listing standards and the Company's Corporate Governance Guidelines.
- Mr. Andrews was also appointed to the Nominating and Corporate Governance Committee of the Board.
- Mr. Andrews is currently serving as Founder, Managing Partner of The Bethesda Group, which is a strategic consulting firm focused on helping organizations in the molecular diagnostic/genomic market segments with strategy, commercial execution, C-suite mentorship and fractional C suite support.
- From April 2023 to July 2024, Mr. Andrews served as President and CEO of Twin Strand Biosciences, from July 2016 to December 2022 as President and CEO of Oncocyte Inc. (NASDAQ: OCX).
- From July 2015 to July 2019 he worked as Founder and Senior Partner of The Bethesda Group and from September 2013 to February 2015 he was President, Genetic Sciences Division, at Thermo Fisher Scientific/ Life Technologies (NASDAQ:TMO).
Reported
(3) On June 11, 2024, Dr. LaFrance stepped down from his position as the Company's Chief Medical Officer.
- On January 9, 2026, Plus Therapeutics, Inc. (the "Company") filed a Registration Statement on Form S-1 (File No. 333-292637) with the Securities and Exchange Commission (as amended, the "Registration Statement").
- On February 9, 2026, the Compensation Committee approved discretionary cash bonuses payable to the Named Executive Officers for Fiscal Year 2025.
- In accordance with SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions computed in accordance with ASC Topic 718.
- (2) This column includes standard benefits, including a 401K match, and health and life insurance premiums.
Tools for this story
Each opens in a new tab, filled in for Cerenome, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
